RNU6-362P

Across TCGA pan-cancer cohorts, RNU6-362P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNU6-362P data layer.

The strongest signal is observed in mesothelioma (MESO), where higher RNU6-362P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-362P expression acts as an unfavorable survival marker.

MESO, DLBC, and ACC are the cancer types where RNU6-362P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	III,IV	0.082	0.414	.007	54	view →
DLBC	DFS	Tertile	III,IV	0.137	0.790	<.001	45	view →
ACC	OS	Tertile	All	0.188	0.820	<.001	36	view →
LIHC	OS	Tertile	All	0.061	0.783	<.001	36	view →
BRCA	DFS	Tertile	II,III,IV	0.719	0.891	.023	18	view →
LUSC	OS	Tertile	III,IV	0.178	0.683	.040	18	view →
STAD	DFS	Tertile	IV	0.141	0.539	.049	9	view →
PRAD	OS	Tertile	All	0.952	0.996	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RNU6-362P–MESO (DFS)

Open the MESO breakdown →